In patients with either FLT3-ITD or FLT3-TKD mutations, which are considered poor prognostic factors for AML, gilteritinib exhibits antitumor activity by inhibiting tyrosine kinases against FLT3 mutations. The gene discussed is FLT3; the disease is acute myeloid leukemia.